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Abstract 
VAD, (Vincristine, Doxorubicin and Dexamethasone) was initially proposed as a salvage therapy for myeloma patients in whom prior 
alkylating agent therapy failed, although in recent years VAD has been surpassed by novel combination therapies with new biological 
agents such as thalidomide (and its derivative, lenalidomide) and bortezomib.  After the excellent results obtained by the novel agents, 
VAD can no longer be proposed in preparation to autologous transplantation, although there are still indications that VAD remains useful 
and clinically relevant in the initial treatment of symptomatic multiple myeloma.  
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Multiple myeloma (MM) is a tumour of mature isotype-switched 
plasma cells that accumulate in the bone marrow causing 
anaemia, hypercalcemia, bone lesions and renal impairment in 
at least 30% of cases [1]. 
Melphalan, the first alkylating agent, introduced in 1958, was 
later supplemented with prednisone to form the MP regimen [2–
3]. It has been the mainstay of conventional therapy for several 
decades, although the response rate is no more than 50% with 
less than 5% CR and an overall survival (OS) not exceeding 
three years [4–6]. Melphalan is easy to use on an outpatient 
basis and has a relative low toxicity profile. However it should 
be used with caution in patients with renal failure [7] and should 
be avoided in patients who are candidates for stem cell 
collection and autologous stem cell transplantation (SCT) 
because of its myelotoxicity [8–9]. In order to improve the 
efficacy of MP regimen, other combination treatments have 
been explored. 
VAD, (vincristine, doxorubicin and dexamethasone) was initially 
proposed as a salvage therapy for myeloma patients in whom 
prior alkylating agent therapy failed [10]. In comparison to MP, 
VAD presents several advantages including a more rapid 
response (maximum response obtained after two courses), no 
dose reduction required in cases of impaired renal function and, 
importantly, it does not influence the stem cell collection as it is 
not toxic for hematological precursors. Since 1989 this 
combination became the most widely used induction regimen in 
preparation for autologous transplantation [11–12]. According to 
SWOG criteria, the overall response rate was 84%, with 28% 
complete remission when used as first line treatment [11]. 
Successive studies on the efficacy of VAD estimated overall 
response rate between 50% and 60%, according to standard 
criteria of Bladé et al [13]. In recent years the popularity of VAD 
has been tempered by the promising preliminary results of new 
biological agents such as thalidomide (and its derivative, 
lenalidomide) and bortezomib and due to its haematological 
(granulocytopenia and thrombocytopenia) and non-
haematological toxicity (neurotoxicity and impaired cardiac 
function). A further disadvantage of VAD is the risk of catheter-
related infections and thrombosis. Infections are reported to be 
the main side effect of VAD and seem to be related to steroid 
and concomitant granulocytopenia: 30–35% of patients had 
infectious episodes in some institutions [14]. 
In order to decrease some of the most relevant toxicities of 
conventional VAD without the detrimental effect on efficacy, we 
proposed a less intensive VAD in preparation for intensified 
chemotherapy and subsequent autologous transplant. 
 
Methods 
Between January 1997 to January 2007, a ‘modified VAD’ was 
given to 56 previously untreated multiple myeloma patients as 
induction therapy prior to autologous transplantation. (Table 1: 
Patients’ characteristics). Median age was 58 years (range 44–
67); according to Durie and Salmon classification eight patients 
were stage I with an evident progression (I PD), nine patients 
were stage II and 39 patients were stage III. Monoclonal 
immunoglobulin subtypes were as follows: IgG in 28 patients 
(50%), IgA in 13 patients (23%), light chains in ten patients 
(18%) and five patients (9%) had a non-secretory myeloma. Out 
of the 56 patients, ten received only modified VAD while 46 
patients went on to receive intensified high-dose chemotherapy 
supported by autologous stem cell transplantation (tandem 
transplant: 38 patients; single transplant: eight patients). The 
conditioning regimens are listed in Table 2 . The response 
criteria were defined according to Bladé et al consensus 
guidelines [13]: a complete remission (CR) was defined as no 
detectable monoclonal component in serum immunofixation, no 
evidence of Bence-Jones paraprotein in the urine and less than 
5% morphologically and phenotypically normal plasma cells in 
the bone marrow. A partial remission (PR) was defined as a 
decrease of at least 50% serum and urine M-protein, a very 
good partial remission (VGPR) as a decrease of 90% serum M-
component in both serum and urine and a near complete 
remission (nCR) was obtained when no detectable M-protein is 
present on serum immunoelectrophoresis but with a positive 
immunofixation. No response was defined as stable disease or 
disease progression. The modified VAD schedule was delivered 
as follows: a continuous infusion of vincristine (0.4mg/sqm) and 
doxorubicin (9mg/sqm) on days 1–3, and dexamethasone 40mg 
per day intravenous on days 1–3 and then orally on days 4 and 
5 of each cycle. The timing of steroid administration differed to 
that of the standard VAD regimen of oral administration on days 
1–4, 9–12 and 17–21 [15–16]. 
The treatment cycles were repeated at four-weekly intervals 
with an average of four cycles (range 2–8). No antimicrobial 
prophylaxis was proposed. 
 



















Table 1: Patients’ characteristics 




















Table 2: Conditioning regimens 
 
Table 3: Response to modified VAD 
The validation of the modified schedule in terms of efficacy and 




The overall response rate (CR, nCR, VGPR, PR) was 60%: CR 
and nCR 10%, VGPR and PR 50%, SD 40% (Table 3 : 
Response to treatment). These results confirmed those 
observed in the first ten consecutive patients investigated in the 
interim analysis. The response was independent of stage of 
disease and of the monoclonal immunoglobulin and light chain 
type. 
Ten patients who received modified VAD alone were excluded 
from the intensification and subsequent SCT for the following 
reasons: hepatitis and a DVT in one patient after the first two 
cycles of modified VAD; failed stem mobilization in two patients 
who went on to alternative therapy; bilateral pneumonia in one 
patient after the second cycle and was considered at high risk of 
complications from successive intensification. One patient had 
an aggressive breast cancer progression (breast cancer 
diagnosed prior to myeloma) after mobilization and was shifted 
to the appropriate treatment; one patient had hepatic 
progression and received salvage therapy; one patient was lost 
to follow-up after mobilization; one patient did not accept 
transfusions. One responding patient (PR) was a candidate for 
transplantation but could not proceed due to a lung infection 
after high-dose cyclophosphamide for SC mobilization. One 
patient (nCR) was lost to follow-up after the first two modified 
VAD cycles. 
Three patients (5%) developed pneumonia of unknown origin, 
which was resolved with antifungal and antimicrobial 
combination therapy in all cases. Only one serious reversible 
neurological event (paralytic ileus) occurred. Liver toxicity 
(grade 2 WHO) caused a delay of therapy and a subsequent 
dose reduction in one patient. 
No patients developed grade 3 or 4 granulocytopenia and/or 
thrombocytopenia. Eight out of 56 patients (14%) developed 
transient granulocytopenia G1, and 12 patients (21%) 
thrombocytopenia G1. No cumulative haematological toxicity 
was observed. Importantly, the reduced-intensity schedule did 
not affect stem cell mobilization capability: the median value of 
collected CD34+cells in the 46 mobilized patients was 
9.0x106/kg (range 2.8–45.6). In almost all cases (>90%) one 
leucapheretic procedure was enough for collection. The 
monoclonal plasma cell contamination in the leucapheresis 
product was not evaluated. 
Nausea, fatigue, constipation, peripheral neuropathy and skin 
rashes occurred but they were mild (G1 WHO) and reversible in 
all cases. Cardiac function was monitored by echocardiography 
in the first 32 consecutively treated patients before and after 
modified VAD, all of which maintained the same level of cardiac 



















function and so the remaining patients were not given 
echocardiograms. 
Deep venous thrombosis was clinically evident and diagnosed 
by ultrasound in five patients (9%). 
The patients who received only VAD showed a time to 
progression (TTP) of 6.8 months (range 2–18 months) while for 
the 46 intensified patients who obtained an overall response 




Although in recent years VAD has been surpassed by novel 
combination therapies (Thal+Dex, Bortezomib+Thal+Dex, 
Bortezomib+Dex) as frontline strategies for multiple myeloma 
patients, standard treatment has not yet been identified. 
Nowadays in many European and North American cancer 
institutes VAD is still proposed as induction treatment in 
preparation for autologous SC transplantation. Certainly the 
need for a central venous catheter, G2 and G3 (WHO) 
granulocytopenia as well as the potential for cardiac toxicity 
have played an important role in drawing conclusions about 
VAD-related deaths. In order to overcome the severe side 
effects as a result of the regimen's toxicity, we modified the 
standard VAD by reducing the duration of administration of the 
three components of the schedule as reported before above. 
We believe that a less intensive regimen could translate into a 
reduced toxicity profile but may also decrease the overall 
response rate. In our single institution experience with 56 
previously untreated patients, an overall response rate of 60% 
was obtained, in comparison to 60–65% as reported in the 
historical data. The best response (2% CR + 4% nCR) occurred 
in 10% of the patients compared to 7% with a CR with standard 
VAD [17]. Importantly we obtained a very low side effect rate in 
comparison to the standard VAD schedule. Regarding 
haematological toxicity, no patient experienced G3–G4 (WHO) 
granulocytopenia and only 12% of the patients had G1 (WHO) 
transient intercycle granulocytopenia which did not cause a 
delay in therapy in any case. With standard VAD, G3 
granulocytopenia was registered in 12% of patients [17], 
probably as a consequence of low-dose dexamethasone. No 
life-threatening infectious complications occurred during and 
after treatment with the modified VAD: pneumonia occurred in 
5% of patients but was resolved with conventional antimicrobial 
therapy. 
Only one serious reversible neurological event (paralytic ileus) 
was registered during the ultimate cycle of treatment in one 
patient, in contrast G3 (WHO) neuropathy is often observed 
during standard VAD. 
We observed five thrombotic events (9% of patients) mostly 
related to the central venous catheter (three events), indicating 
that local mechanical trauma and not the thrombogenic potential 
of the chemotherapy was the cause of this complication (7% in 
the literature) [17]. 
Moreover our schedule seems to be safe in terms of cardiac 
function: LVEF was always within normal limits (>60%) in all the 
32 patients given modified VAD. 
Over the last ten years the debate has been ongoing about the 
best initial treatment for multiple myeloma in order to obtain the 
best response in preparation for dose intensification and 
transplant: CR, nCR and VGPR status prior to high-dose 
chemotherapy seems to correlate with better EFS and OS post-
transplantation [18]. Novel thalidomide-based combination 
therapies (Thal/Dex [19], Thal/MP [20], Thal/Dex/PegLD [21], 
Lenalidomide-based: Lenalidomide/Dex [22], Claritromycin/ 
Lenalidomide/Dex [23], Lenalidomide/MP [24] and bortezomib-
based: Bortezomib/Dex [25], Bortezomib/DT-Pace [26], 
Bortezomib/Adria/Dex [27], Bortezomib/Thal/Dex [28], 
Bortezomib/MP [29]) represent a promising future as first line 
myeloma treatments. Preliminary results in pivotal studies state 
their superiority in terms of response rate (up to 95% with 
Bortezomib/Adriamycin/Dex). The favorable impact on stem cell 
mobilization would suggest a crucial role of these new 
combinations in the induction phase prior to the intensification 
therapy with single or tandem autologous transplantation. In this 
scenario, the role of VAD in preparation for autologous 
transplant is surely under discussion. 
 
Conclusions 
After the excellent results obtained by the novel agents, VAD 
can no longer be proposed in preparation to autologous 
transplantation, although there are still indications that VAD 
remains useful and clinically relevant in the initial treatment of 
symptomatic MM [22]. 
The results of this small study demonstrate that 'modified VAD' 
is comparable to 'classic VAD' in terms of efficacy with a better 
safety profile. Further because of the favourable toxic profile of 
this less intensive VAD scheme, modified VAD could be 
considered as an alternative therapeutic option in the elderly if a 
large tumour burden is present and when a rapid response in 
symptomatic patients is needed. 
Moreover the modified VAD could also play a role in relapsed 
disease, as indicated in the NCCN guidelines 2009 [30]. 
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